Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabics is a standardized medical cannabis extract in capsule form developed by Cannabics Pharmaceuticals for the treatment of cancer-related cachexia and anorexia syndrome (CACS). The formulation contains a specific ratio of cannabinoids, primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC acts as a partial agonist at the Cannabinoid receptor 1 (CB1), which is known to stimulate appetite and modulate energy metabolism, while CBD provides complementary effects and may mitigate some of the psychoactive side effects of THC. The drug was evaluated in a Phase 2 pilot study to assess its ability to improve appetite and prevent weight loss in advanced cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cannabics.